Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12315177 | 1.00 | HTR3A (0.45) | HTR3ACYP1A2CYP2C19RAB9ACHRNA7 | |
| SCHEMBL1965990 | 0.89 | HTR3A (0.46) | HTR3ACYP1A2CYP2C19RAB9ACHRNA7 | |
| SCHEMBL1965988 | 0.89 | HTR3A (0.46) | HTR3ACYP1A2CYP2C19RAB9ACHRNA7 | |
| SCHEMBL2790861 | 0.86 | HTR3A (0.44) | HTR3ACYP1A2CYP2C19RAB9ACHRNA7 | |
| SCHEMBL5993662 | 0.85 | HTR3A (0.43) | HTR3ACYP1A2CYP2C19RAB9ACHRNA7 | |
| SCHEMBL1964527 | 0.85 | HTR3A (0.43) | HTR3ACYP1A2CYP2C19RAB9ACHRNA7 | |
| SCHEMBL491877 | 0.84 | HTR3A (0.46) | HTR3ACYP1A2CYP2C19RAB9ACHRNA7 | |
| SCHEMBL1966475 | 0.84 | CHRNA7 (0.43) | HTR3ACHRNA7 | |
| SCHEMBL1963750 | 0.83 | HTR3A (0.46) | HTR3ACYP1A2CYP2C19RAB9ACHRNA7 | |
| SCHEMBL5995484 | 0.83 | HTR3A (0.46) | HTR3ACYP1A2CYP2C19RAB9ACHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319407-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | XIE WENGE (US) | 2011-12-29 | — | — | US | claimed |
| US-20100105677-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2010-04-29 | — | — | US | claimed |
| US-20050234095-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2005-10-20 | — | — | US | claimed |
| US-20130217683-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2013-08-22 | — | — | US | disclosed |
| US-8486937-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and use thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2013-07-16 | — | — | US | disclosed |
| US-8263619-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110319407-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | XIE WENGE (US) | 2011-12-29 | — | — | US | disclosed |
| EP-2336128-A1 | Benzoisothiazoles and preparation and uses thereof | Memory Pharmaceuticals Corporation (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100105677-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2010-04-29 | — | — | US | disclosed |
| US-20050234095-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319407-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | CHRNA7, CHRNA5, CHRNA3 | HTR3A 352/4885CYP1A2 935/4885CYP2C19 1326/4885 |
| US-20100105677-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA3 | HTR3A 367/4885CYP1A2 929/4885CYP2C19 1331/4885 |
| US-20130217683-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | CHRNA7, CHRNA5, CHRNA3 | HTR3A 352/4885CYP1A2 935/4885CYP2C19 1326/4885 |
| US-20050234095-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA3 | HTR3A 367/4885CYP1A2 929/4885CYP2C19 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.